Dabigatran etexilate
- PDF / 169,244 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 77 Downloads / 171 Views
1 S
Gastrointestinal bleeding: case report In a prospective, non-interventional, non-controlled, multicenter, observational study involving 653 patients, an 81-year-old woman* was described, who developed gastrointestinal bleeding during treatment with dabigatran etexilate for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF). The woman, who was receiving unspecified vitamin-K antagonist for the prevention of stroke and systemic embolism in NVAF, started receiving treatment with dabigatran etexilate twice daily [route and dose not stated]. Subsequently, she developed gastrointestinal bleeding secondary to the dabigatran etexilate therapy and died because of it [duration of treatment to reaction onset not stated]. * Patient demographics received via mail correspondence with the author. Barrios V, et al. Patients’ perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists. Journal of Comparative Effectiveness 803520660 Research 9: 615-625, No. 9, Jun 2020. Available from: URL: http://doi.org/10.2217/cer-2020-0001
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
